Dyspnea and Post-Pulmonary Embolism Syndrome after a Mild COVID-19 Infection [0.03%]
轻度COVID-19感染后出现呼吸困难和肺栓塞综合征
Namratha S Meda,John H Sherner,Aaron B Holley
Namratha S Meda
Survival and Long-Term Functional Status of COVID-19 Patients Requiring Prolonged Extracorporeal Membrane Oxygenation Support [0.03%]
需要延长体外膜肺氧合支持的COVID-19患者的生存率及其长期的功能状态
María Martínez-Martínez,Matthieu Schmidt,Lars Mikael Broman et al.
María Martínez-Martínez et al.
Rationale: Severe cases of acute respiratory distress syndrome (ARDS) may require prolonged (>28 d) extracorporeal membrane oxygenation (ECMO). In nonresolving disease, recovery is uncertain, and lung transplant may be proposed. Objectives:...
Observational Study
Annals of the American Thoracic Society. 2024 Mar;21(3):449-455. DOI:10.1513/AnnalsATS.202306-572OC 2024
Risk of 30-Day All-Cause Readmission in Interstitial Lung Disease Patients after COVID-19: National-Level Data [0.03%]
COVID-19后间质性肺疾病患者的30天内所有原因再入院风险：国家级数据
Ali Vaeli Zadeh,Roshan Dinparastisaleh,Atefeh Vaezi et al.
Ali Vaeli Zadeh et al.
Rationale: Hospital readmission within 30 days poses challenges for healthcare providers, policymakers, and patients because of its impact on care quality, costs, and outcomes. Patients with interstitial lung disease (ILD) are particularly ...
Practice Patterns and Outcomes of Potassium Repletion Thresholds during Critical Illness [0.03%]
重症期间补钾阈值的实践模式和结果
Nicholas A Bosch,Emily A Vail,Anica C Law et al.
Nicholas A Bosch et al.
Rationale: Potassium repletion is common in critically ill patients. However, practice patterns and outcomes related to different intensive care unit (ICU) potassium repletion strategies are unclear. Objectives: 1) Describe potassium replet...
Risk of Chronic Obstructive Pulmonary Disease (COPD) Hospitalizations and Deaths among Rural and Urban Veterans after Successive COPD Hospitalizations [0.03%]
农村和城市退伍军人在多次慢性阻塞性肺疾病(COPD)住院治疗后出现慢性阻塞性肺疾病(COPD)住院和死亡的风险
Spyridon Fortis,Yubo Gao,Peter J Kaboli et al.
Spyridon Fortis et al.
Validation of Constant Work Rate Cycling Endurance Time for Use in Chronic Obstructive Pulmonary Disease Clinical Trials [0.03%]
用于慢性阻塞性肺疾病临床试验的恒定负荷骑行耐力时间的有效性
Richard Casaburi,Debora Merrill,Nancy Kline Leidy et al.
Richard Casaburi et al.
Rationale: A COPD Foundation working group sought to identify measures of exercise endurance, a meaningful aspect of physical functioning in everyday life among patients with chronic obstructive pulmonary disease (COPD) that is not fully ac...
Impact of the COVID-19 Pandemic on Outcomes of CAPTURE: A Primary Care Chronic Obstructive Pulmonary Disease Screening Clinical Trial [0.03%]
CAPTURE试验在COVID-19大流行期间的实施情况及结果分析
Barbara P Yawn,Barry Make,David Mannino et al.
Barbara P Yawn et al.
Impact of Air Pollution and MUC5B Genotype on Survival in Idiopathic Pulmonary Fibrosis [0.03%]
空气污染和MUC5B基因型对特发性肺纤维化生存率的影响
Lucile Sesé,Raphaël Borie,Caroline Kannengiesser et al.
Lucile Sesé et al.
The Impact of Occupational Exposures on the Risk of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis [0.03%]
职业暴露与特发性肺纤维化发病风险关联的系统评价和meta分析
Sheiphali A Gandhi,Bohyung Min,Jane C Fazio et al.
Sheiphali A Gandhi et al.
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic pulmonary disorder of unknown etiology that is characterized by a usual interstitial pneumonia pattern. Previous meta-analyses have reported associations between occup...
Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study [0.03%]
持续气道正压通气而不是通过GLP-1减轻体重可改善阻塞性睡眠呼吸暂停的早期心血管疾病：一项概念验证性随机研究
Cliona O&#x;Donnell,Shane Crilly,Anne O&#x;Mahony et al.
Cliona O&#x;Donnell et al.
Rationale: Obstructive sleep apnea (OSA) is an independent risk factor for cardiovascular (CV) morbidity and mortality, but the benefit of continuous positive airway pressure (CPAP) is uncertain. However, most randomized controlled trials h...
Randomized Controlled Trial
Annals of the American Thoracic Society. 2024 Mar;21(3):464-473. DOI:10.1513/AnnalsATS.202309-821OC 2024